Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+

  Prostate Cancer

  Free Subscription


1 Acta Radiol
4 BJU Int
1 BMC Cancer
1 BMC Urol
3 Br J Radiol
1 Cancer Imaging
2 Eur J Radiol
1 Eur Radiol
5 Eur Urol
3 Int J Cancer
1 Int J Urol
1 J Magn Reson Imaging
1 J Nucl Med
4 J Urol
2 PLoS One
1 Prostate
3 Urology

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Acta Radiol

  1. ARTEAGA-MARRERO N, Mainou-Gomez JF, Brekke Rygh C, Lutay N, et al
    Radiation treatment monitoring with DCE-US in CWR22 prostate tumor xenografts.
    Acta Radiol. 2019;60:788-797.
    PubMed     Text format     Abstract available

    BJU Int

  2. MURPHY DG, Hofman MS, Azad A, Violet J, et al
    Going nuclear - It is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team.
    BJU Int. 2019 May 24. doi: 10.1111/bju.14814.
    PubMed     Text format     Abstract available

  3. YAXLEY JW, Raveenthiran S, Nouhaud FX, Samaratunga H, et al
    Risk of metastatic disease on (68) Ga-PSMA PET/CT scan for primary staging of 1253 men at the diagnosis of prostate cancer.
    BJU Int. 2019 May 29. doi: 10.1111/bju.14828.
    PubMed     Text format     Abstract available

  4. MAZZONE E, Mistretta FA, Knipper S, Palumbo C, et al
    Long-Term Incidence of Secondary Bladder, Rectal Cancer in Patients Treated with Brachytherapy for Localized Prostate Cancer: A Large-Scale Population-Based Analysis.
    BJU Int. 2019 May 30. doi: 10.1111/bju.14841.
    PubMed     Text format     Abstract available

  5. HOSTIOU T, Gelet A, Chapelon JY, Rouviere O, et al
    Salvage high-intensity focused ultrasound for locally recurrent prostate cancer after low-dose-rate brachytherapy: oncologic and functional outcomes.
    BJU Int. 2019 May 30. doi: 10.1111/bju.14838.
    PubMed     Text format     Abstract available

    BMC Cancer

  6. WERUTSKY G, Maluf FC, Cronemberger EH, Carrera Souza V, et al
    The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels.
    BMC Cancer. 2019;19:487.
    PubMed     Text format     Abstract available

    BMC Urol

  7. JANSSEN S, Fahlbusch FB, Kasmann L, Rades D, et al
    Radiotherapy for prostate cancer: DISCERN quality assessment of patient-oriented websites in 2018.
    BMC Urol. 2019;19:42.
    PubMed     Text format     Abstract available

    Br J Radiol

  8. KING AJ, Dudderidge T, Darekar A, Schimitz K, et al
    Establishing magnetic resonance imaging guided prostate intervention at a UK Centre.
    Br J Radiol. 2019 Mar 26:20180918. doi: 10.1259/bjr.20180918.
    PubMed     Text format     Abstract available

  9. DE LEON J, Jameson MG, Rivest-Henault D, Keats S, et al
    Reduced motion and improved rectal dosimetry through endorectal immobilization for prostate stereotactic body radiotherapy.
    Br J Radiol. 2019;92:20190056.
    PubMed     Text format     Abstract available

  10. LEE SM, Wolfe K, Acher P, Liyanage SH, et al
    Multiparametric MRI appearances of primary granulomatous prostatitis.
    Br J Radiol. 2019 Apr 9:20180075. doi: 10.1259/bjr.20180075.
    PubMed     Text format     Abstract available

    Cancer Imaging

  11. LU YF, Zhang Q, Yao WG, Chen HY, et al
    Optimizing prostate cancer accumulating model: combined PI-RADS v2 with prostate specific antigen and its derivative data.
    Cancer Imaging. 2019;19:26.
    PubMed     Text format     Abstract available

    Eur J Radiol

  12. ULLRICH T, Arsov C, Quentin M, Laqua N, et al
    Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients.
    Eur J Radiol. 2019;113:1-6.
    PubMed     Text format     Abstract available

  13. LINDGREN BELAL S, Sadik M, Kaboteh R, Enqvist O, et al
    Deep learning for segmentation of 49 selected bones in CT scans: First step in automated PET/CT-based 3D quantification of skeletal metastases.
    Eur J Radiol. 2019;113:89-95.
    PubMed     Text format     Abstract available

    Eur Radiol

  14. XIANG LH, Fang Y, Wan J, Xu G, et al
    Shear-wave elastography: role in clinically significant prostate cancer with false-negative magnetic resonance imaging.
    Eur Radiol. 2019 May 29. pii: 10.1007/s00330-019-06274.
    PubMed     Text format     Abstract available

    Eur Urol

  15. COOPERBERG MR, Carroll PR, Dall'Era MA, Davies BJ, et al
    The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement.
    Eur Urol. 2019 May 23. pii: S0302-2838(19)30417.
    PubMed     Text format     Abstract available

  16. FROEHNER M, Thomas C
    Re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol 2019;75:552
    Eur Urol. 2019 May 23. pii: S0302-2838(19)30419.
    PubMed     Text format    

  17. HADASCHIK B, Ost P
    Re: Assessment of (68)Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.
    Eur Urol. 2019 May 23. pii: S0302-2838(19)30420.
    PubMed     Text format    

  18. KASIVISVANATHAN V, Stabile A, Neves JB, Giganti F, et al
    Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis.
    Eur Urol. 2019 May 23. pii: S0302-2838(19)30360.
    PubMed     Text format     Abstract available

  19. KOSCHEL SG, Wong LM, Heinze S, Zargar H, et al
    Re: Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging.
    Eur Urol. 2019 May 27. pii: S0302-2838(19)30424.
    PubMed     Text format    

    Int J Cancer

  20. STRAND SH, Bavafaye-Haghighi E, Kristensen H, Rasmussen A, et al
    A novel combined miRNA and methylation marker panel (miMe) for prediction of prostate cancer outcome after radical prostatectomy.
    Int J Cancer. 2019 May 24. doi: 10.1002/ijc.32427.
    PubMed     Text format     Abstract available

  21. ALSHALALFA M, Liu Y, Wyatt AW, Gibb EA, et al
    Characterization of Transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma.
    Int J Cancer. 2019 May 24. doi: 10.1002/ijc.32430.
    PubMed     Text format     Abstract available

  22. GAO X, Wilsgaard T, Jansen EH, Xuan Y, et al
    Serum total thiol levels and the risk of lung, colorectal, breast and prostate cancer: A prospective case-cohort study.
    Int J Cancer. 2019 May 24. doi: 10.1002/ijc.32428.
    PubMed     Text format     Abstract available

    Int J Urol

  23. NAKAMURA K, Konishi K, Komatsu T, Ishiba R, et al
    Quality of life after external beam radiotherapy for localized prostate cancer: Comparison with other modalities.
    Int J Urol. 2019 May 26. doi: 10.1111/iju.14026.
    PubMed     Text format     Abstract available

    J Magn Reson Imaging

  24. GHOLIZADEH N, Greer PB, Simpson J, Fu C, et al
    Supervised risk predictor of central gland lesions in prostate cancer using (1) H MR spectroscopic imaging with gradient offset-independent adiabaticity pulses.
    J Magn Reson Imaging. 2019 May 27. doi: 10.1002/jmri.26803.
    PubMed     Text format     Abstract available

    J Nucl Med

  25. ZACHO H, Jochumsen MR, Langkilde NC, Mortensen JC, et al
    No added value of (18)F-sodium fluoride PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer with normal bone scintigraphy.
    J Nucl Med. 2019 May 30. pii: jnumed.119.229062. doi: 10.2967/jnumed.119.229062.
    PubMed     Text format     Abstract available

    J Urol

  26. FAISAL FA, Tosoian JJ, Han M, Macura KJ, et al
    Clinical, Pathological and Oncologic Findings of Radical Prostatectomy with Extraprostatic Extension Diagnosed on Preoperative Prostate Biopsy.
    J Urol. 2019;201:937-942.
    PubMed     Text format     Abstract available

  27. MURALIDHAR V, Mahal BA, Butler S, Lamba N, et al
    Combined external beam radiation therapy and brachytherapy versus radical prostatectomy with adjuvant radiation therapy for Gleason 9-10 prostate cancer.
    J Urol. 2019 May 30:101097JU0000000000000352. doi: 10.1097/JU.0000000000000352.
    PubMed     Text format     Abstract available

  28. GROSS MD, Sedrakyan A, Bianco FJ, Carroll PR, et al
    Study of Prostate Ablation Related Energy Devices (SPARED) Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer.
    J Urol. 2019 May 30:101097JU0000000000000357. doi: 10.1097/JU.0000000000000357.
    PubMed     Text format     Abstract available

  29. HANNA N, Wszolek MF, Mojtahed A, Nicaise E, et al
    J Urol. 2019 May 30:101097JU0000000000000359. doi: 10.1097/JU.0000000000000359.
    PubMed     Text format     Abstract available

    PLoS One

  30. ARMSTRONG AJ, Gupta S, Healy P, Kemeny G, et al
    Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
    PLoS One. 2019;14:e0216934.
    PubMed     Text format     Abstract available

  31. KARUNASINGHE N, Symes E, Gamage A, Wang A, et al
    Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand.
    PLoS One. 2019;14:e0217373.
    PubMed     Text format     Abstract available


  32. HU WY, Xu L, Chen B, Ou S, et al
    Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75.
    Prostate. 2019;79:1166-1179.
    PubMed     Text format     Abstract available


    Reply by Author: "New Evidence for the Benefits of Prostate-Specific Antigen Screening".
    Urology. 2019;125:261-262.
    PubMed     Text format    

    Editorial Comment.
    Urology. 2019;125:160-161.
    PubMed     Text format    

    Concerns With "New Evidence for the Benefits of Prostate-specific Antigen Screening: Data from 400,887 Kaiser Permanente Patients".
    Urology. 2019;125:261.
    PubMed     Text format    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.